Abstract
The aim of this study is to report the efficacy of topical Mitomycin-C (MMC) as adjunctive treatment following primary excision of ocular surface squamous neoplasia (OSSN).After detailed evaluation, 25 eyes in 25 patients with localized primary OSSN were selected in a prospective, interventional study and subjected to primary excision followed by the application of topical 0.04% MMC as an adjunct and thereafter followed up over a 24 month period for signs of any tumor recurrence. The 25 patients selected with primary OSSN had a mean age of 64(SD 13) with a range of 47-87 years. They underwent surgical excision followed by 3 cycles of freshly prepared 0.04% MMC with 2 weeks on and 2 weeks off for 12weeks.All patients were followed up thereafter at 1 week, 2 weeks, monthly for 6 months and every 3 months for the next 24 months. No tumor recurrence was observed in any of the cases.Topical MMC has a definite role in preventing tumor recurrence when used as adjunctive treatment following primary surgical excision of OSSN.
Highlights
Ocular surface squamous neoplasia (OSSN) encompasses a spectrum of epithelial squamous malignancies, that range from mild to severe dysplasia to invasive squamous cell carcinoma. 1 The incidence of OSSN across the world has been reported to be 0.02-3.5 cases per 100,000, 2 with a greater frequency in regions near the equator. 3 OSSN generally presents in the late sixth to seventh decades of life, but has been seen to occur earlier in people who are immunocompromised. 4 Several risk factors have been implicated in causing OSSN which include UV light exposure, an immunocompromised state as in HIV and Human Papilloma Virus infection, 5 smoking, 6 advanced age and male gender. 7The mainstay of treatment of OSSN involves surgical excision
We undertook a study of 25 eyes in 25 patients with localized primary OSSN who were treated with surgical excision and topical Mitomycin -C(MMC) as an adjunct and have reported the recurrence rate after a follow -up period of 24 months
The study conducted was a hospital based, prospective interventional study that involved 25 eyes of 25 patients with localized OSSN who presented between January 2017 to January 2020
Summary
Ocular surface squamous neoplasia (OSSN) encompasses a spectrum of epithelial squamous malignancies, that range from mild to severe dysplasia to invasive squamous cell carcinoma. 1 The incidence of OSSN across the world has been reported to be 0.02-3.5 cases per 100,000, 2 with a greater frequency in regions near the equator. 3 OSSN generally presents in the late sixth to seventh decades of life, but has been seen to occur earlier in people who are immunocompromised. 4 Several risk factors have been implicated in causing OSSN which include UV light exposure, an immunocompromised state as in HIV and Human Papilloma Virus infection, 5 smoking, 6 advanced age and male gender. 7The mainstay of treatment of OSSN involves surgical excision. 1 The incidence of OSSN across the world has been reported to be 0.02-3.5 cases per 100,000, 2 with a greater frequency in regions near the equator. 3 OSSN generally presents in the late sixth to seventh decades of life, but has been seen to occur earlier in people who are immunocompromised. 7. The mainstay of treatment of OSSN involves surgical excision. A high rate of recurrence has been observed following surgical excision alone. We undertook a study of 25 eyes in 25 patients with localized primary OSSN who were treated with surgical excision and topical Mitomycin -C(MMC) as an adjunct and have reported the recurrence rate after a follow -up period of 24 months
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
